Strides Pharma Science Ltd

- Strides Pharma is continuing to invest in CAPEX for ongoing needs in India and the US despite net debt reduction efforts. - Network optimization program has been completed, including mothballing the Singapore facility and shifting production to Chestnut Ridge, US. - The company is focusing on building its CDMO business (OneSource) with detailed plans for growth to $160 million in launch year and $400 million by FY27. - No explicit mention of new large-scale strategic or inorganic investments for Strides; focus remains on consolidation, debt reduction, and organic growth. - Arun Kumar indicated for the next 2-3 quarters, the priority is improving cash-to-cash cycle and reducing debt; no inorganic growth planned for Strides during this period. - CAPEX efforts support competitive positioning, manufacturing robustness, and product approvals, especially for US and other regulated markets.

- US business targeted to reach $400 million in sales within 2 financial years, maintaining margin profile (Page 8, 9). - New product launches expected to be significant drivers, with 3-4 products having $20 million+ exit run rates by year-end (Page 8). - Other regulated markets to grow as mirrored markets to the US; expected to reach similar size in about 4 to 4.5 years, with current run rate around $200 million (Page 10). - Growth markets and access markets anticipated to become equally important in next 2-3 years (Page 5). - CDMO business (OneSource) projected to hit approximately $160 million in launch year and $400 million by FY27 (Page 11). - Overall company revenue growth targeted at around 15-16%, with stronger H2 performance expected (Page 5).

- Strides targets $400 million revenue in US business within 2 years while maintaining current margin profiles. - US growth driven by high-value product launches, with 3-4 products expected to hit $20 million+ exit run rates by year-end. - Other regulated markets aimed to mirror US market size (~$400 million), expected over 4 to 4.5 years. - EBITDA expected around Rs. 950 crores next year despite divestment of Rs. 150 crores EBITDA to OneSource. - Focus on stable operating expenses (~$200 million annually) to boost EBITDA and PAT margins. - Network optimization and asset sales improve EBITDA and earnings flow-through by about Rs. 60 crores annually. - Margin improvements from restructuring and mothballing of less viable facilities support EPS growth. - Anticipated strong free cash flow generation aiding debt reduction and enhancing PAT conversion. - Growth markets expected to become as important as regulated markets in 2-3 years, providing additional earnings potential.

- The company reported a strong order book in H2 FY24 with several product approvals recently received, including a critical product and generic Vascepa. - There is a large order book for contract manufacturing opportunities led by GLP in OneSource. - The CDMO business OneSource has a backlog driven by approximately 14-15 customers with a peak revenue potential of about $300 million in GLP programs, contingent on regulatory approvals and market access. - The company has significant R&D income from development and filing batches for customers, with commercial supplies expected to start gradually around FY25 and main patterns extending to 2030. - The ongoing product approvals and site changes (from Chestnut Ridge to India) are intended to enhance competitiveness and manufacturing robustness. Overall, the order book is healthy with strong visibility on contracts and expected growth through regulatory approvals and market launches.

- No explicit mention of any new fundraising through debt or equity in the current earnings call transcript. - Focus is on debt reduction: targeted debt reduction of about Rs. 700 crores between Strides and OneSource. - Net debt to EBITDA ratio has improved significantly (from ~8x in FY22 to about 3.3x in H1 FY24), with a target to reduce it below 3 in FY24. - Emphasis on free cash generation, reducing cash-to-cash cycle, and improving operating efficiency to manage working capital and debt. - Management focuses on consolidation and debt reduction over the next 2-3 quarters rather than inorganic growth or raising new funds. - No immediate plans for significant inorganic growth or capital raising; preference is consolidating existing operations and improving financial health.